argenx announces Annual General Meeting of Shareholders on May 10, 2022
March 29 2022 - 4:30PM
March
29,
2022
Breda, the Netherlands – argenx
SE (Euronext & Nasdaq: ARGX), a global immunology company
committed to improving the lives of people suffering from severe
autoimmune diseases, today announced that an annual general meeting
of shareholders will be held at 10:00 a.m. CEST on Tuesday May 10,
2022 at the Hilton Amsterdam Airport Schiphol, Schiphol Boulevard
701, 1118 BG Schiphol, the Netherlands. The shareholders and all
other persons with meeting rights are invited to attend the annual
general meeting of shareholders.
The formal notice of convocation (including
information on attending the meeting in person or by proxy,
requirements for notification and registration for the meeting and
regarding the e-voting system) is available on the argenx website
www.argenx.com/investors/shareholder-meetings and on
www.abnamro.com/evoting.
AgendaThe full agenda for the
meeting as well as all ancillary documents relevant for the meeting
are available via the argenx website and are also available for
inspection at the argenx offices. A free copy thereof may also be
obtained by e-mailing annualmeeting@argenx.com.
In addition to recurrent items on the agenda,
such as the discussion and adoption of the 2021 Annual Accounts, an
advisory vote on the company’s 2021 remuneration report, the
discharge of the directors for their duties performed in 2021 and
the authorization of the Board of Directors to issue shares and to
limit or exclude pre-emptive rights in relation thereto, the
following items, amongst others, are proposed:
- Re-appointment of Tim van
Hauwermeiren as executive director to the Board of Directors;
- Re-appointment of Peter K.M.
Verhaeghe, James Michael Daly and Werner Lanthaler as non-executive
directors to the Board of Directors;
- Amendment of the articles of
association to align with current Dutch law and practice and to
grant a proxy to each of the directors of argenx and employees of
Freshfields Bruckhaus Deringer LLP, Amsterdam office to execute the
deed of amendment of the articles of association; and
- Appointment of Deloitte Accountants
B.V. for the 2022 financial year.
argenx would like to encourage shareholders to
use the voting by (electronic) proxy option as referred to in the
convocation. The Company will provide a live audio-webcast of the
general meeting to enable as many shareholders as possible to
attend.
About argenx argenx is a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases. Partnering with
leading academic researchers through its Immunology Innovation
Program (IIP), argenx aims to translate immunology breakthroughs
into a world-class portfolio of novel antibody-based medicines.
argenx developed and is commercializing the first-and-only approved
neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The
Company is evaluating efgartigimod in multiple serious autoimmune
diseases and advancing several earlier stage experimental medicines
within its therapeutic franchises. For more information, visit
www.argenx.com and follow us on LinkedIn, Twitter,
and Instagram.
For further information, please
contact:
Media:
Kelsey Kirkkkirk@argenx.com
Joke Comijn jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
argenx (NASDAQ:ARGX)
Historical Stock Chart
From Jul 2023 to Jul 2024